Chloramphenicol Toxicity

⚙

Pathophysiology

9

Systemic Chloramphenicol Exposure

Chloramphenicol given systemically (intravenous or oral) reaches host tissues. This circulating drug is the common initiator of toxicity; the dose at which it harms depends on how well the patient clears it.

Downstream

Mitochondrial Ribosomal Protein-Synthesis Inhibition

Chronic Chloramphenicol Neurotoxicity A toxicity of prolonged exposure whose mechanism is not established, so it is placed off the exposure node rather than the mitochondrial chain.

Idiosyncratic Bone Marrow Aplasia A rare, dose-independent arm that can follow any route of exposure; the mechanism linking exposure to stem-cell injury is not established.

Impaired Neonatal Hepatic Glucuronidation

Neonates, especially premature infants, have immature hepatic UDP-glucuronosyltransferase activity and immature renal excretion, so they cannot conjugate and clear chloramphenicol. A standard weight-based dose therefore accumulates to toxic serum concentrations - the basis of neonatal susceptibility to gray baby syndrome.

Downstream

Systemic Chloramphenicol Exposure Deficient clearance raises and prolongs circulating drug in the neonate, so a normal dose behaves as an overdose.

Show evidence (1 reference)

PMID:41602900 SUPPORT REVIEW SYNTHESIS Human Clinical

"Newborns, particularly preterm infants, have underdeveloped livers and relatively low glucuronidation capacity, making them highly susceptible to chloramphenicol toxicity and the highest-risk group for gray baby syndrome"

States the immature-glucuronidation susceptibility that is this node's claim.

Mitochondrial Ribosomal Protein-Synthesis Inhibition

Chloramphenicol inhibits the peptidyl-transferase of the bacterial 50S ribosomal subunit; the mitochondrial ribosome is bacterial-like, so the drug also blocks mitochondrial protein synthesis in host cells, injuring mitochondria and impairing synthesis of respiratory-chain subunits.

mitochondrial translation GO:0032543 ↓ DECREASED

Downstream

Oxidative Phosphorylation Failure

Show evidence (2 references)

PMID:2486534 SUPPORT REVIEW SYNTHESIS Other

"The common, dose-dependent, reversible bone marrow suppression from chloramphenicol is a consequence of mitochondrial injury."

Attributes the dose-dependent marrow toxicity to mitochondrial injury, the lesion this node represents.

PMID:23118672 SUPPORT REVIEW SYNTHESIS Other

"This binding inhibits the mitochondrial enzyme peptidyl transferase, which is necessary for peptide bond formation."

Names the molecular target - inhibition of mitochondrial peptidyl transferase - underlying this node.

Oxidative Phosphorylation Failure

Depressed synthesis of mitochondrially encoded respiratory-chain subunits lowers oxidative phosphorylation and causes cellular necrosis, the shared cellular lesion behind both the dose-dependent marrow suppression and the gray baby toxidrome.

oxidative phosphorylation GO:0006119 ↓ DECREASED

Downstream

Dose-Dependent Bone Marrow Suppression

Gray Baby Toxidrome

Myocardial Dysfunction and Microcirculatory Failure

Show evidence (1 reference)

PMID:41602900 SUPPORT REVIEW SYNTHESIS Other

"Chloramphenicol overdose inhibits mitochondrial protein synthesis, which disrupts oxidative phosphorylation and causes cellular necrosis."

Names the mitochondrial-translation to oxidative-phosphorylation to necrosis step this node represents.

Dose-Dependent Bone Marrow Suppression

The mitochondrial lesion depresses erythropoiesis in a dose-dependent, reversible way; the erythroid lineage is most susceptible, reflecting its reliance on mitochondrial amino-acid pools. Anaemia resolves on stopping the drug.

erythroid progenitor cell CL:0000038

Downstream

Anemia

Reticulocytopenia

Thrombocytopenia

Show evidence (2 references)

PMID:2486534 SUPPORT REVIEW SYNTHESIS Other

"The greater erythroid susceptibility to chloramphenicol appears to be a function of the endogenous mitochondrial amino acid pools."

Explains the erythroid predominance of the dose-dependent suppression this node describes.

PMID:23118672 SUPPORT BACKGROUND Human Clinical

"a predictable dose-dependent toxicity resulting in anemia that was reversible upon drug withdrawal"

Second source for the dose-dependent, reversible nature of this marrow arm.

Gray Baby Toxidrome

In the accumulating neonate, mitochondrial energetic failure manifests as the gray baby toxidrome - vomiting, abdominal distension, hypothermia, an ashen-gray colour, cyanosis and metabolic acidosis - which, together with the circulatory collapse driven by the myocardial/microcirculatory arm, carries a high mortality. The features appear together; this node fans out to them rather than one causing the next.

Downstream

Ashen-gray discoloration

Cyanosis

Hypothermia

Vomiting

Abdominal distension

Metabolic acidosis

Respiratory distress

Show evidence (2 references)

PMID:41602900 SUPPORT BACKGROUND Human Clinical

"Gray baby syndrome is a severe adverse reaction to chloramphenicol, with a mortality rate up to 40%."

Quantifies the high mortality of the syndrome this node represents.

PMID:42073156 SUPPORT REVIEW SYNTHESIS Other

"characterised by abdominal distension, vomiting, respiratory distress, hypothermia, hypotension, progressive cyanosis, and ash-grey skin discolouration"

Peer-reviewed enumeration of the toxidrome features this node fans out to.

Myocardial Dysfunction and Microcirculatory Failure

At high exposure the drug and the resulting cellular necrosis release vasoactive substances and cause myocardial damage, reducing cardiac output and peripheral perfusion - the proposed hemodynamic bridge from the cellular lesion to overt circulatory collapse. In the cited case this limb was documented (reduced ejection fraction recovering with treatment).

Downstream

Circulatory collapse

Show evidence (1 reference)

PMID:41602900 SUPPORT REVIEW SYNTHESIS Human Clinical

"At high doses, the drug also induces myocardial damage and dysfunction"

Names the myocardial-dysfunction intermediate between the cellular lesion and circulatory collapse.

Chronic Chloramphenicol Neurotoxicity

Prolonged chloramphenicol exposure produces a neurotoxicity - optic neuritis, often with peripheral neuropathy - separate from the acute neonatal syndrome. Across the reported cases it follows prolonged, high-cumulative-dose therapy (mean ~229 days and ~255 g at the time of neurologic findings), which is the discriminator that sets this chronic arm apart from the acute toxidrome. Its mechanism is not established; direct neurotoxicity, hypersensitivity and vitamin B deficiency have all been proposed, and the vitamin-deficiency hypothesis underlies the B12/B6 treatment sometimes used. It is therefore placed off the exposure node rather than the mitochondrial chain.

Downstream

Optic neuritis

Peripheral neuropathy

Show evidence (3 references)

PMID:23118672 SUPPORT Human Clinical

"Optic neuritis is the most common neurotoxicity and can often be accompanied by peripheral neuropathy"

Documents the optic neuritis and accompanying peripheral neuropathy of prolonged chloramphenicol exposure.

PMID:23118672 SUPPORT REVIEW SYNTHESIS Other

"The mechanism(s) of neurotoxicity is unknown. Direct neurotoxicity, hypersensitivity, and vitamin B deficiency have been speculated."

Source states the mechanism is unresolved, which is why this node is not attributed to the mitochondrial lesion.

PMID:23118672 SUPPORT REVIEW SYNTHESIS Human Clinical

"the mean duration of chloramphenicol therapy at the time of neurologic findings was 229 days (range, 10-1513 days), with a mean total exposure dose of 255 grams"

Quantifies the prolonged, high-cumulative-dose exposure that distinguishes the chronic neurotoxicity arm, pooled across 54 reported patients.

Idiosyncratic Bone Marrow Aplasia

A rare, dose-independent, often fatal aplastic anaemia that is not explained by the mitochondrial mechanism. The pathogenesis is uncertain; the leading hypothesis is metabolic transformation of the drug's p-NO2 (nitro) group into a toxic intermediate that damages haematopoietic stem cells in susceptible people, and it can appear after exposure has ended.

Downstream

Aplastic anemia

Show evidence (4 references)

PMID:2486534 SUPPORT REVIEW SYNTHESIS Other

"The pathogenesis of aplastic anemia from chloramphenicol treatment remains uncertain."

Supports treating the aplastic-anaemia arm as mechanistically unresolved.

PMID:2486534 SUPPORT REVIEW SYNTHESIS Other

"A large body of indirect evidence favors a complex mechanism involving metabolic transformation of the p-NO2 group of chloramphenicol by the predisposed subject, leading to the production of a toxic intermediate causing stem cell damage."

Gives the leading nitro-metabolite hypothesis for stem-cell injury in this arm.

PMID:23118672 SUPPORT BACKGROUND Human Clinical

"an idiosyncratic reaction resulting in aplastic anemia that was unpredictable, irreversible, and frequently fatal, occurring with an incidence of 1 case in 24,000 to 40,000 courses of therapy"

Gives the dose-independent, irreversible character and the incidence of this arm.

+ 1 more reference

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

14

Blood 4

Anemia HP:0001903

Show evidence (1 reference)

PMID:2486534 SUPPORT REVIEW SYNTHESIS Other

"The common, dose-dependent, reversible bone marrow suppression from chloramphenicol is a consequence of mitochondrial injury."

Establishes the reversible marrow suppression (anaemia) this phenotype records.

Aplastic anemia HP:0001915

Show evidence (1 reference)

PMID:9723830 SUPPORT Human Clinical

"An association between ocular chloramphenicol and aplastic anaemia cannot be excluded. However, the risk is less than one per million treatment courses."

Documents chloramphenicol-associated aplastic anaemia and its rarity.

Reticulocytopenia HP:0001896

Show evidence (1 reference)

PMID:23118672 SUPPORT Human Clinical

"anemia, thrombocytopenia, reticulocytopenia, and severe metabolic acidosis"

Documents reticulocytopenia in a patient with chloramphenicol marrow toxicity.

Thrombocytopenia HP:0001873

Show evidence (1 reference)

PMID:23118672 SUPPORT Human Clinical

"anemia, thrombocytopenia, reticulocytopenia, and severe metabolic acidosis"

Documents thrombocytopenia in a patient with chloramphenicol marrow toxicity.

Cardiovascular 1

Circulatory collapse Shock HP:0031273

Show evidence (1 reference)

PMID:41602900 SUPPORT BACKGROUND Human Clinical

"Infants receiving excessive doses of chloramphenicol are at risk of fatal cardiovascular collapse, a condition known as gray baby syndrome"

Names cardiovascular collapse as the defining severe event.

Digestive 2

Vomiting HP:0002013

Show evidence (1 reference)

PMID:28846297 SUPPORT REVIEW SYNTHESIS Other

"they began to develop abdominal distention, vomiting, hypothermia, cyanosis, and cardiovascular instability"

Lists vomiting among the early gray-baby features.

Abdominal distension Abdominal distention HP:0003270

Show evidence (1 reference)

PMID:28846297 SUPPORT REVIEW SYNTHESIS Other

"they began to develop abdominal distention, vomiting, hypothermia, cyanosis, and cardiovascular instability"

Lists abdominal distension among the early gray-baby features.

Eye 1

Optic neuritis HP:0100653

Show evidence (1 reference)

PMID:23118672 SUPPORT Human Clinical

"neutropenia, visual field changes, and peripheral neuropathy"

Documents the visual-field (optic) manifestation of prolonged chloramphenicol toxicity.

Integument 1

Cyanosis HP:0000961

Show evidence (1 reference)

PMID:28846297 SUPPORT REVIEW SYNTHESIS Other

"they began to develop abdominal distention, vomiting, hypothermia, cyanosis, and cardiovascular instability"

Lists cyanosis among the defining gray-baby features, distinct from the ashen-gray discoloration.

Metabolism 2

Hypothermia HP:0002045

Show evidence (1 reference)

PMID:28846297 SUPPORT REVIEW SYNTHESIS Other

"they began to develop abdominal distention, vomiting, hypothermia, cyanosis, and cardiovascular instability"

Lists hypothermia among the defining gray-baby features.

Metabolic acidosis HP:0001942

Show evidence (1 reference)

PMID:41602900 SUPPORT REVIEW SYNTHESIS Human Clinical

"Notably, metabolic acidosis is regarded as an early indicator of chloramphenicol toxicity"

Names metabolic acidosis as an early indicator of the toxicity.

Nervous System 1

Peripheral neuropathy HP:0009830

Show evidence (1 reference)

PMID:23118672 SUPPORT Human Clinical

"neutropenia, visual field changes, and peripheral neuropathy"

Documents peripheral neuropathy of prolonged chloramphenicol toxicity.

Respiratory 1

Respiratory distress HP:0002098

Show evidence (1 reference)

PMID:42073156 SUPPORT REVIEW SYNTHESIS Other

"characterised by abdominal distension, vomiting, respiratory distress, hypothermia, hypotension, progressive cyanosis, and ash-grey skin discolouration"

Lists respiratory distress among the gray baby toxidrome features.

Other 1

Ashen-gray discoloration

Show evidence (2 references)

PMID:28846297 SUPPORT REVIEW SYNTHESIS Other

"Vasomotor collapse resulting in mottling of skin and eventual ashen-gray skin discoloration led to the naming of this reaction as"

Documents the ashen-gray discoloration that names the syndrome.

PMID:41602900 SUPPORT REVIEW SYNTHESIS Human Clinical

"The characteristic clinical presentation includes hypotonia, lethargy, ashen-gray skin discoloration, cyanosis, abdominal distension, impaired peripheral perfusion, hypotension, hypothermia, and metabolic acidosis"

Peer-reviewed confirmation of the ashen-gray discoloration in the characteristic presentation.

💊

Medical Actions

3

Drug discontinuation and supportive care

Action: Supportive Care NCIT:C15747

Stopping chloramphenicol and supporting circulation, ventilation and temperature; the mainstay for gray baby syndrome and dose-dependent marrow suppression.

Show evidence (1 reference)

PMID:41602900 SUPPORT Human Clinical

"Aggressive management included mechanical ventilation, inotropic support (dopamine/milrinone), norepinephrine infusion"

Documents the intensive supportive care used for severe gray baby syndrome.

Extracorporeal drug removal

Action: continuous renal replacement therapy Ontology label: Renal Replacement Therapy NCIT:C126400

Continuous renal replacement therapy (the intervention used in the cited case), with exchange transfusion or charcoal haemoperfusion as alternatives, to clear massively accumulated chloramphenicol in severe toxicity. Bound to the renal-replacement action; NCIT exchange-transfusion (NCIT:C173284) is not reachable from the TreatmentTerm root (NCIT:C25218), so it is named in prose only.

Show evidence (2 references)

PMID:41602900 SUPPORT Human Clinical

"delayed CRRT proved pivotal in reversing toxicity in our patient"

Reports extracorporeal removal (CRRT) reversing severe accumulation.

PMID:23118672 SUPPORT Human Clinical

"hemodialysis was initiated for severe metabolic acidosis"

A further case of extracorporeal removal (haemodialysis) for severe chloramphenicol toxicity.

Vitamin B12 and B6 supplementation

Action: Pharmacotherapy NCIT:C15986

Agent: hydroxocobalamin (vitamin B12) CHEBI:27786 pyridoxine (vitamin B6) CHEBI:16709

Platform: Small molecule

Large doses of vitamin B12 and B6 are given for chloramphenicol optic neuritis on the vitamin-deficiency hypothesis of the neurotoxicity. The benefit is unproven: in the cited case, hydroxocobalamin and pyridoxine did not recover the patient's vision. Recorded as a documented therapeutic approach with its outcome, not as an established treatment.

Show evidence (2 references)

PMID:23118672 SUPPORT REVIEW SYNTHESIS Human Clinical

"Treatment involves discontinuing chloramphenicol and the consideration of large doses of vitamin B12 and B6."

States the B12/B6 approach to chloramphenicol neurotoxicity.

PMID:23118672 SUPPORT Human Clinical

"this therapy was not successful in improving his vision"

Documents the failure of B12/B6 therapy to recover vision in the cited case.

🌍

Environmental Factors

1

Systemic chloramphenicol administration

The exposure is iatrogenic: chloramphenicol given as antibiotic therapy, by intravenous or oral route. Toxicity follows when a neonate cannot clear a standard dose, at higher exposures in any patient, or idiosyncratically.

Show evidence (1 reference)

PMID:28846297 SUPPORT REVIEW SYNTHESIS Other

"Neonates born at less than 37 weeks gestation were given chloramphenicol in an intravenous or oral formulation within two days of birth"

Establishes the iatrogenic systemic administration that is the exposure.

Mechanism Target:

TRIGGERS Systemic Chloramphenicol Exposure — Administered chloramphenicol is the source of the circulating drug that drives host toxicity.

🔬

Diagnosis

3

Clinical recognition and serum concentration

Diagnosis rests on a temporal link to chloramphenicol exposure with a compatible toxidrome, supported by a serum chloramphenicol concentration; high levels predict severe toxicity and death, which is also the basis for therapeutic monitoring in neonates.

Show evidence (2 references)

PMID:41602900 SUPPORT REVIEW SYNTHESIS Human Clinical

"fatal cases consistently showing serum chloramphenicol levels exceeding 50"

Supports serum concentration as a diagnostic and prognostic measurement.

PMID:42073156 SUPPORT REVIEW SYNTHESIS Other

"The occurrence of grey baby syndrome is generally associated with serum levels exceeding 50 mg/L, so levels should generally be maintained between 15 and 25 mg/L"

Gives the toxic threshold and therapeutic target range (in mg/L) that make serum monitoring actionable.

Blood count monitoring during therapy

Serial complete blood counts during treatment detect the dose-dependent marrow suppression early, before it is severe.

Show evidence (2 references)

PMID:41602900 SUPPORT REVIEW SYNTHESIS Other

"The guidelines emphasize the necessity of regular blood-count monitoring during treatment."

Directly supports regular blood-count monitoring during chloramphenicol therapy.

PMID:42073156 SUPPORT REVIEW SYNTHESIS Other

"Monitoring should be performed before starting therapy with this drug and then every 3 to 4 days"

Gives the monitoring cadence (baseline then every 3-4 days).

Metabolic acidosis as an early indicator

An early metabolic acidosis in an exposed neonate is a practical early warning of chloramphenicol toxicity, often preceding overt collapse.

Show evidence (1 reference)

PMID:41602900 SUPPORT REVIEW SYNTHESIS Human Clinical

"Notably, metabolic acidosis is regarded as an early indicator of chloramphenicol toxicity"

Names metabolic acidosis as the stated early indicator used in diagnosis.

📊

Prevalence

1

Reported gray baby syndrome cases in the literature

Cases In Literature Ultra Rare

A 2025 case report plus literature review analysed 19 other published cases; of the 17 with outcomes, 35.3% (6/17) died. Gray baby syndrome is now rare but persists in resource-limited settings.

Show evidence (2 references)

PMID:41602900 SUPPORT Human Clinical

"Besides his case, 19 other published cases were analyzed."

Establishes the literature case count behind this CASES_IN_LITERATURE record.

PMID:41602900 SUPPORT Human Clinical

"Literature analysis revealed 64.7% survival (11/17) and 35.3% mortality (6/17)"

Reports the pooled survival/mortality across the reviewed cases.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Chloramphenicol Toxicity:

Other causes of aplastic anemia

Overlapping Features Aplastic anaemia has many drug, toxic, viral and idiopathic causes that overlap with the idiosyncratic chloramphenicol form.

Distinguishing Features

A documented chloramphenicol exposure within the aetiological window points to the drug, though the attributable risk per course is very low.

Show evidence (1 reference)

PMID:9723830 SUPPORT Human Clinical

"An association between ocular chloramphenicol and aplastic anaemia cannot be excluded. However, the risk is less than one per million treatment courses."

The low attributable risk is why exposure history, not the finding alone, distinguishes the drug cause.

Neonatal sepsis and septic shock

Overlapping Features The gray baby toxidrome - hypotension, poor perfusion, hypothermia, metabolic acidosis and feeding intolerance in a neonate - closely mimics neonatal sepsis with septic shock, the first diagnosis most such infants receive.

Distinguishing Features

A temporal link to chloramphenicol administration and an elevated serum chloramphenicol concentration point to toxicity; sepsis is supported by a positive culture or an identified infective focus.
Gray baby syndrome improves on stopping and clearing the drug, whereas septic shock requires source control and antimicrobials.

{ }

Source YAML

click to show

name: Chloramphenicol Toxicity
creation_date: "2026-10-06T00:00:00Z"
category: Complex
categories:
- Treatment Toxicity
- Toxic Exposure Disorder
parents:
- Drug Toxicity
- Poisoning
synonyms:
- chloramphenicol poisoning
- gray baby syndrome
- grey baby syndrome
- chloramphenicol-induced bone marrow suppression
- chloramphenicol-induced aplastic anemia
description: >-
  Chloramphenicol toxicity is the systemic toxicity syndrome of the broad-spectrum
  antibiotic chloramphenicol, which inhibits the peptidyl-transferase of the
  bacterial 50S ribosomal subunit and, because the mitochondrial ribosome is
  bacterial-like, also inhibits mitochondrial protein synthesis in host cells.
  Three largely distinct clinical forms are recognised. A dose-dependent,
  reversible bone-marrow suppression (predominantly erythroid, with anaemia) is a
  direct consequence of mitochondrial injury and resolves on withdrawal. In
  neonates - whose hepatic glucuronidation and renal excretion are immature - the
  drug accumulates to toxic serum concentrations and produces the "gray baby
  syndrome": vomiting, abdominal distension, hypothermia, an ashen-gray colour,
  hypotension and cardiovascular collapse. A third form, idiosyncratic aplastic
  anaemia, is rare, dose-independent, can follow any route of exposure (including
  topical/ocular), is often fatal, and has an uncertain mechanism thought to
  involve a toxic nitro-reduction metabolite in susceptible people - it is not
  explained by the mitochondrial mechanism and is modelled here as a separate arm.
  Management is stopping the drug and supportive care, with serum-concentration
  monitoring and, for massive accumulation, extracorporeal drug removal.
disease_term:
  preferred_term: chloramphenicol toxicity
  term:
    id: MONDO:0010784
    label: chloramphenicol toxicity
notes: >-
  Deliberately curated as one entry spanning the three forms. The dose-dependent
  marrow suppression and the gray baby syndrome share the mitochondrial-injury
  mechanism and are wired through it; idiosyncratic aplastic anaemia is kept as a
  separate, mechanistically distinct arm off the exposure node rather than
  downstream of the mitochondrial lesion (Yunis PMID:2486534 frames them as
  separate). The neonatal glucuronidation defect is developmental immaturity of
  UDP-glucuronosyltransferase; the isoform usually named for chloramphenicol
  glucuronidation is UGT2B7 (not the bilirubin enzyme UGT1A1), but no gene is
  bound on the glucuronidation node because no primary source naming the isoform
  was verified in this curation.
prevalence:
- population: Reported gray baby syndrome cases in the literature
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    A 2025 case report plus literature review analysed 19 other published cases;
    of the 17 with outcomes, 35.3% (6/17) died. Gray baby syndrome is now rare but
    persists in resource-limited settings.
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Besides his case, 19 other published cases were analyzed."
    explanation: Establishes the literature case count behind this CASES_IN_LITERATURE record.
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Literature analysis revealed 64.7% survival (11/17) and 35.3% mortality (6/17)"
    explanation: Reports the pooled survival/mortality across the reviewed cases.
references:
- reference: PMID:28846297
  title: "Gray Baby Syndrome (Archived)."
  tags:
  - StatPearls
pathophysiology:
- name: Systemic Chloramphenicol Exposure
  description: >-
    Chloramphenicol given systemically (intravenous or oral) reaches host tissues.
    This circulating drug is the common initiator of toxicity; the dose at which
    it harms depends on how well the patient clears it.
  biological_scale: ORGANISM
  downstream:
  - target: Mitochondrial Ribosomal Protein-Synthesis Inhibition
    causal_link_type: DIRECT
  - target: Chronic Chloramphenicol Neurotoxicity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A toxicity of prolonged exposure whose mechanism is not established, so it
      is placed off the exposure node rather than the mitochondrial chain.
  - target: Idiosyncratic Bone Marrow Aplasia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A rare, dose-independent arm that can follow any route of exposure; the
      mechanism linking exposure to stem-cell injury is not established.
    evidence:
    - reference: PMID:9723830
      reference_title: "Possible association between ocular chloramphenicol and aplastic anaemia--the absolute risk is very low."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "An association between ocular chloramphenicol and aplastic anaemia cannot be excluded. However, the risk is less than one per million treatment courses."
      explanation: >-
        Shows aplastic anaemia can follow even topical/ocular exposure and is very
        rare, consistent with a dose-independent idiosyncratic arm.
- name: Impaired Neonatal Hepatic Glucuronidation
  description: >-
    Neonates, especially premature infants, have immature hepatic
    UDP-glucuronosyltransferase activity and immature renal excretion, so they
    cannot conjugate and clear chloramphenicol. A standard weight-based dose
    therefore accumulates to toxic serum concentrations - the basis of neonatal
    susceptibility to gray baby syndrome.
  biological_scale: MOLECULAR
  downstream:
  - target: Systemic Chloramphenicol Exposure
    causal_link_type: DIRECT
    description: >-
      Deficient clearance raises and prolongs circulating drug in the neonate, so
      a normal dose behaves as an overdose.
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Newborns, particularly preterm infants, have underdeveloped livers and relatively low glucuronidation capacity, making them highly susceptible to chloramphenicol toxicity and the highest-risk group for gray baby syndrome"
    explanation: >-
      States the immature-glucuronidation susceptibility that is this node's claim.
- name: Mitochondrial Ribosomal Protein-Synthesis Inhibition
  conforms_to: "xenobiotic_oxidative_phosphorylation_blockade#Xenobiotic Blockade of Mitochondrial Respiration"
  description: >-
    Chloramphenicol inhibits the peptidyl-transferase of the bacterial 50S
    ribosomal subunit; the mitochondrial ribosome is bacterial-like, so the drug
    also blocks mitochondrial protein synthesis in host cells, injuring
    mitochondria and impairing synthesis of respiratory-chain subunits.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: mitochondrial translation
    term:
      id: GO:0032543
      label: mitochondrial translation
    modifier: DECREASED
  downstream:
  - target: Oxidative Phosphorylation Failure
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:2486534
    reference_title: "Chloramphenicol toxicity: 25 years of research."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The common, dose-dependent, reversible bone marrow suppression from chloramphenicol is a consequence of mitochondrial injury."
    explanation: >-
      Attributes the dose-dependent marrow toxicity to mitochondrial injury, the
      lesion this node represents.
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "This binding inhibits the mitochondrial enzyme peptidyl transferase, which is necessary for peptide bond formation."
    explanation: >-
      Names the molecular target - inhibition of mitochondrial peptidyl
      transferase - underlying this node.
- name: Oxidative Phosphorylation Failure
  conforms_to: "xenobiotic_oxidative_phosphorylation_blockade#Cellular ATP Depletion despite Preserved Oxygen Delivery"
  description: >-
    Depressed synthesis of mitochondrially encoded respiratory-chain subunits
    lowers oxidative phosphorylation and causes cellular necrosis, the shared
    cellular lesion behind both the dose-dependent marrow suppression and the
    gray baby toxidrome.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  downstream:
  - target: Dose-Dependent Bone Marrow Suppression
    causal_link_type: DIRECT
  - target: Gray Baby Toxidrome
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Myocardial Dysfunction and Microcirculatory Failure
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Chloramphenicol overdose inhibits mitochondrial protein synthesis, which disrupts oxidative phosphorylation and causes cellular necrosis."
    explanation: >-
      Names the mitochondrial-translation to oxidative-phosphorylation to necrosis
      step this node represents.
- name: Dose-Dependent Bone Marrow Suppression
  description: >-
    The mitochondrial lesion depresses erythropoiesis in a dose-dependent,
    reversible way; the erythroid lineage is most susceptible, reflecting its
    reliance on mitochondrial amino-acid pools. Anaemia resolves on stopping the
    drug.
  biological_scale: TISSUE
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  downstream:
  - target: Anemia
    causal_link_type: DIRECT
  - target: Reticulocytopenia
    causal_link_type: DIRECT
  - target: Thrombocytopenia
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:2486534
    reference_title: "Chloramphenicol toxicity: 25 years of research."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The greater erythroid susceptibility to chloramphenicol appears to be a function of the endogenous mitochondrial amino acid pools."
    explanation: >-
      Explains the erythroid predominance of the dose-dependent suppression this
      node describes.
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "a predictable dose-dependent toxicity resulting in anemia that was reversible upon drug withdrawal"
    explanation: >-
      Second source for the dose-dependent, reversible nature of this marrow arm.
- name: Gray Baby Toxidrome
  description: >-
    In the accumulating neonate, mitochondrial energetic failure manifests as the
    gray baby toxidrome - vomiting, abdominal distension, hypothermia, an
    ashen-gray colour, cyanosis and metabolic acidosis - which, together with the
    circulatory collapse driven by the myocardial/microcirculatory arm, carries a
    high mortality. The features appear together; this node fans out to them
    rather than one causing the next.
  biological_scale: ORGANISM
  downstream:
  - target: Ashen-gray discoloration
    causal_link_type: DIRECT
  - target: Cyanosis
    causal_link_type: DIRECT
  - target: Hypothermia
    causal_link_type: DIRECT
  - target: Vomiting
    causal_link_type: DIRECT
  - target: Abdominal distension
    causal_link_type: DIRECT
  - target: Metabolic acidosis
    causal_link_type: DIRECT
  - target: Respiratory distress
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Gray baby syndrome is a severe adverse reaction to chloramphenicol, with a mortality rate up to 40%."
    explanation: Quantifies the high mortality of the syndrome this node represents.
  - reference: PMID:42073156
    reference_title: "Potentially Hazardous Drugs in the Paediatric ICU: A Narrative Review on the Exemplary Cases of Propofol, Chloramphenicol, and Acetylsalicylic Acid."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "characterised by abdominal distension, vomiting, respiratory distress, hypothermia, hypotension, progressive cyanosis, and ash-grey skin discolouration"
    explanation: Peer-reviewed enumeration of the toxidrome features this node fans out to.
- name: Myocardial Dysfunction and Microcirculatory Failure
  description: >-
    At high exposure the drug and the resulting cellular necrosis release
    vasoactive substances and cause myocardial damage, reducing cardiac output and
    peripheral perfusion - the proposed hemodynamic bridge from the cellular lesion
    to overt circulatory collapse. In the cited case this limb was documented
    (reduced ejection fraction recovering with treatment).
  biological_scale: ORGANISM
  downstream:
  - target: Circulatory collapse
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "At high doses, the drug also induces myocardial damage and dysfunction"
    explanation: >-
      Names the myocardial-dysfunction intermediate between the cellular lesion and
      circulatory collapse.
- name: Chronic Chloramphenicol Neurotoxicity
  description: >-
    Prolonged chloramphenicol exposure produces a neurotoxicity - optic neuritis,
    often with peripheral neuropathy - separate from the acute neonatal syndrome.
    Across the reported cases it follows prolonged, high-cumulative-dose therapy
    (mean ~229 days and ~255 g at the time of neurologic findings), which is the
    discriminator that sets this chronic arm apart from the acute toxidrome.
    Its mechanism is not established; direct neurotoxicity, hypersensitivity and
    vitamin B deficiency have all been proposed, and the vitamin-deficiency
    hypothesis underlies the B12/B6 treatment sometimes used. It is therefore
    placed off the exposure node rather than the mitochondrial chain.
  biological_scale: ORGANISM
  downstream:
  - target: Optic neuritis
    causal_link_type: DIRECT
  - target: Peripheral neuropathy
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Optic neuritis is the most common neurotoxicity and can often be accompanied by peripheral neuropathy"
    explanation: >-
      Documents the optic neuritis and accompanying peripheral neuropathy of
      prolonged chloramphenicol exposure.
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The mechanism(s) of neurotoxicity is unknown. Direct neurotoxicity, hypersensitivity, and vitamin B deficiency have been speculated."
    explanation: >-
      Source states the mechanism is unresolved, which is why this node is not
      attributed to the mitochondrial lesion.
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "the mean duration of chloramphenicol therapy at the time of neurologic findings was 229 days (range, 10-1513 days), with a mean total exposure dose of 255 grams"
    explanation: >-
      Quantifies the prolonged, high-cumulative-dose exposure that distinguishes
      the chronic neurotoxicity arm, pooled across 54 reported patients.
- name: Idiosyncratic Bone Marrow Aplasia
  description: >-
    A rare, dose-independent, often fatal aplastic anaemia that is not explained by
    the mitochondrial mechanism. The pathogenesis is uncertain; the leading
    hypothesis is metabolic transformation of the drug's p-NO2 (nitro) group into
    a toxic intermediate that damages haematopoietic stem cells in susceptible
    people, and it can appear after exposure has ended.
  biological_scale: TISSUE
  downstream:
  - target: Aplastic anemia
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:2486534
    reference_title: "Chloramphenicol toxicity: 25 years of research."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The pathogenesis of aplastic anemia from chloramphenicol treatment remains uncertain."
    explanation: Supports treating the aplastic-anaemia arm as mechanistically unresolved.
  - reference: PMID:2486534
    reference_title: "Chloramphenicol toxicity: 25 years of research."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "A large body of indirect evidence favors a complex mechanism involving metabolic transformation of the p-NO2 group of chloramphenicol by the predisposed subject, leading to the production of a toxic intermediate causing stem cell damage."
    explanation: Gives the leading nitro-metabolite hypothesis for stem-cell injury in this arm.
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "an idiosyncratic reaction resulting in aplastic anemia that was unpredictable, irreversible, and frequently fatal, occurring with an incidence of 1 case in 24,000 to 40,000 courses of therapy"
    explanation: >-
      Gives the dose-independent, irreversible character and the incidence of this arm.
  - reference: PMID:42073156
    reference_title: "Potentially Hazardous Drugs in the Paediatric ICU: A Narrative Review on the Exemplary Cases of Propofol, Chloramphenicol, and Acetylsalicylic Acid."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Historically, this adverse event came with a high mortality rate of around 50%"
    explanation: Quantifies the historical mortality of the idiosyncratic aplastic anaemia.
phenotypes:
- name: Ashen-gray discoloration
  description: >-
    Characteristic ashen-gray skin colour of gray baby syndrome, following
    vasomotor collapse - a pallor/hypoperfusion sign the sources list as distinct
    from cyanosis. Left unbound because HPO has no term for ashen-gray skin
    discoloration (searched gray/grey, ashen, skin discoloration); no term beats a
    misleading one, and cyanosis is curated as its own phenotype below.
  phenotype_term:
    preferred_term: Ashen-gray skin discoloration
  evidence:
  - reference: PMID:28846297
    reference_title: "Gray Baby Syndrome (Archived)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Vasomotor collapse resulting in mottling of skin and eventual ashen-gray skin discoloration led to the naming of this reaction as"
    explanation: Documents the ashen-gray discoloration that names the syndrome.
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The characteristic clinical presentation includes hypotonia, lethargy, ashen-gray skin discoloration, cyanosis, abdominal distension, impaired peripheral perfusion, hypotension, hypothermia, and metabolic acidosis"
    explanation: Peer-reviewed confirmation of the ashen-gray discoloration in the characteristic presentation.
- name: Cyanosis
  description: Cyanosis, a distinct gray-baby feature reflecting poor peripheral perfusion/oxygenation.
  phenotype_term:
    preferred_term: Cyanosis
    term:
      id: HP:0000961
      label: Cyanosis
  evidence:
  - reference: PMID:28846297
    reference_title: "Gray Baby Syndrome (Archived)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "they began to develop abdominal distention, vomiting, hypothermia, cyanosis, and cardiovascular instability"
    explanation: Lists cyanosis among the defining gray-baby features, distinct from the ashen-gray discoloration.
- name: Hypothermia
  description: Low body temperature in gray baby syndrome.
  phenotype_term:
    preferred_term: Hypothermia
    term:
      id: HP:0002045
      label: Hypothermia
  evidence:
  - reference: PMID:28846297
    reference_title: "Gray Baby Syndrome (Archived)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "they began to develop abdominal distention, vomiting, hypothermia, cyanosis, and cardiovascular instability"
    explanation: Lists hypothermia among the defining gray-baby features.
- name: Vomiting
  description: Vomiting and feeding intolerance, an early sign of neonatal toxicity.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:28846297
    reference_title: "Gray Baby Syndrome (Archived)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "they began to develop abdominal distention, vomiting, hypothermia, cyanosis, and cardiovascular instability"
    explanation: Lists vomiting among the early gray-baby features.
- name: Abdominal distension
  description: Abdominal distension, a characteristic early feature of gray baby syndrome.
  phenotype_term:
    preferred_term: Abdominal distension
    term:
      id: HP:0003270
      label: Abdominal distention
  evidence:
  - reference: PMID:28846297
    reference_title: "Gray Baby Syndrome (Archived)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "they began to develop abdominal distention, vomiting, hypothermia, cyanosis, and cardiovascular instability"
    explanation: Lists abdominal distension among the early gray-baby features.
- name: Metabolic acidosis
  description: Metabolic acidosis, regarded as an early indicator of chloramphenicol toxicity.
  phenotype_term:
    preferred_term: Metabolic acidosis
    term:
      id: HP:0001942
      label: Metabolic acidosis
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Notably, metabolic acidosis is regarded as an early indicator of chloramphenicol toxicity"
    explanation: Names metabolic acidosis as an early indicator of the toxicity.
- name: Circulatory collapse
  description: Cardiovascular collapse/shock, the lethal hemodynamic endpoint of gray baby syndrome.
  phenotype_term:
    preferred_term: Cardiovascular collapse
    term:
      id: HP:0031273
      label: Shock
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Infants receiving excessive doses of chloramphenicol are at risk of fatal cardiovascular collapse, a condition known as gray baby syndrome"
    explanation: Names cardiovascular collapse as the defining severe event.
- name: Anemia
  description: Dose-dependent, reversible anaemia from erythroid-predominant marrow suppression.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:2486534
    reference_title: "Chloramphenicol toxicity: 25 years of research."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The common, dose-dependent, reversible bone marrow suppression from chloramphenicol is a consequence of mitochondrial injury."
    explanation: Establishes the reversible marrow suppression (anaemia) this phenotype records.
- name: Aplastic anemia
  description: Idiosyncratic, dose-independent aplastic anaemia, often fatal.
  phenotype_term:
    preferred_term: Aplastic anemia
    term:
      id: HP:0001915
      label: Aplastic anemia
  evidence:
  - reference: PMID:9723830
    reference_title: "Possible association between ocular chloramphenicol and aplastic anaemia--the absolute risk is very low."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An association between ocular chloramphenicol and aplastic anaemia cannot be excluded. However, the risk is less than one per million treatment courses."
    explanation: Documents chloramphenicol-associated aplastic anaemia and its rarity.
- name: Reticulocytopenia
  description: Reduced reticulocyte count, reflecting suppressed erythropoiesis in dose-dependent marrow suppression.
  phenotype_term:
    preferred_term: Reticulocytopenia
    term:
      id: HP:0001896
      label: Reticulocytopenia
  evidence:
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "anemia, thrombocytopenia, reticulocytopenia, and severe metabolic acidosis"
    explanation: Documents reticulocytopenia in a patient with chloramphenicol marrow toxicity.
- name: Thrombocytopenia
  description: Low platelet count, a component of chloramphenicol marrow suppression.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "anemia, thrombocytopenia, reticulocytopenia, and severe metabolic acidosis"
    explanation: Documents thrombocytopenia in a patient with chloramphenicol marrow toxicity.
- name: Respiratory distress
  description: Respiratory distress, part of the gray baby toxidrome.
  phenotype_term:
    preferred_term: Respiratory distress
    term:
      id: HP:0002098
      label: Respiratory distress
  evidence:
  - reference: PMID:42073156
    reference_title: "Potentially Hazardous Drugs in the Paediatric ICU: A Narrative Review on the Exemplary Cases of Propofol, Chloramphenicol, and Acetylsalicylic Acid."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "characterised by abdominal distension, vomiting, respiratory distress, hypothermia, hypotension, progressive cyanosis, and ash-grey skin discolouration"
    explanation: Lists respiratory distress among the gray baby toxidrome features.
- name: Optic neuritis
  description: Optic neuritis presenting as visual field changes with prolonged chloramphenicol exposure.
  phenotype_term:
    preferred_term: Optic neuropathy (visual field changes)
    term:
      id: HP:0100653
      label: Optic neuritis
  evidence:
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "neutropenia, visual field changes, and peripheral neuropathy"
    explanation: Documents the visual-field (optic) manifestation of prolonged chloramphenicol toxicity.
- name: Peripheral neuropathy
  description: Peripheral neuropathy with prolonged chloramphenicol exposure.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "neutropenia, visual field changes, and peripheral neuropathy"
    explanation: Documents peripheral neuropathy of prolonged chloramphenicol toxicity.
environmental:
- name: Systemic chloramphenicol administration
  exposure_term:
    preferred_term: exposure to chloramphenicol
    term:
      id: ECTO:9000360
      label: exposure to chloramphenicol
  description: >-
    The exposure is iatrogenic: chloramphenicol given as antibiotic therapy, by
    intravenous or oral route. Toxicity follows when a neonate cannot clear a
    standard dose, at higher exposures in any patient, or idiosyncratically.
  evidence:
  - reference: PMID:28846297
    reference_title: "Gray Baby Syndrome (Archived)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Neonates born at less than 37 weeks gestation were given chloramphenicol in an intravenous or oral formulation within two days of birth"
    explanation: Establishes the iatrogenic systemic administration that is the exposure.
  influences_mechanisms:
  - target: Systemic Chloramphenicol Exposure
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Administered chloramphenicol is the source of the circulating drug that
      drives host toxicity.
diagnosis:
- name: Clinical recognition and serum concentration
  description: >-
    Diagnosis rests on a temporal link to chloramphenicol exposure with a
    compatible toxidrome, supported by a serum chloramphenicol concentration;
    high levels predict severe toxicity and death, which is also the basis for
    therapeutic monitoring in neonates.
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "fatal cases consistently showing serum chloramphenicol levels exceeding 50"
    explanation: Supports serum concentration as a diagnostic and prognostic measurement.
  - reference: PMID:42073156
    reference_title: "Potentially Hazardous Drugs in the Paediatric ICU: A Narrative Review on the Exemplary Cases of Propofol, Chloramphenicol, and Acetylsalicylic Acid."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The occurrence of grey baby syndrome is generally associated with serum levels exceeding 50 mg/L, so levels should generally be maintained between 15 and 25 mg/L"
    explanation: >-
      Gives the toxic threshold and therapeutic target range (in mg/L) that make
      serum monitoring actionable.
- name: Blood count monitoring during therapy
  description: >-
    Serial complete blood counts during treatment detect the dose-dependent
    marrow suppression early, before it is severe.
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The guidelines emphasize the necessity of regular blood-count monitoring during treatment."
    explanation: Directly supports regular blood-count monitoring during chloramphenicol therapy.
  - reference: PMID:42073156
    reference_title: "Potentially Hazardous Drugs in the Paediatric ICU: A Narrative Review on the Exemplary Cases of Propofol, Chloramphenicol, and Acetylsalicylic Acid."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Monitoring should be performed before starting therapy with this drug and then every 3 to 4 days"
    explanation: Gives the monitoring cadence (baseline then every 3-4 days).
- name: Metabolic acidosis as an early indicator
  description: >-
    An early metabolic acidosis in an exposed neonate is a practical early warning
    of chloramphenicol toxicity, often preceding overt collapse.
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Notably, metabolic acidosis is regarded as an early indicator of chloramphenicol toxicity"
    explanation: Names metabolic acidosis as the stated early indicator used in diagnosis.
differential_diagnoses:
- name: Other causes of aplastic anemia
  description: >-
    Aplastic anaemia has many drug, toxic, viral and idiopathic causes that
    overlap with the idiosyncratic chloramphenicol form.
  distinguishing_features:
  - A documented chloramphenicol exposure within the aetiological window points to the drug, though the attributable risk per course is very low.
  evidence:
  - reference: PMID:9723830
    reference_title: "Possible association between ocular chloramphenicol and aplastic anaemia--the absolute risk is very low."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An association between ocular chloramphenicol and aplastic anaemia cannot be excluded. However, the risk is less than one per million treatment courses."
    explanation: The low attributable risk is why exposure history, not the finding alone, distinguishes the drug cause.
- name: Neonatal sepsis and septic shock
  description: >-
    The gray baby toxidrome - hypotension, poor perfusion, hypothermia, metabolic
    acidosis and feeding intolerance in a neonate - closely mimics neonatal sepsis
    with septic shock, the first diagnosis most such infants receive.
  distinguishing_features:
  - A temporal link to chloramphenicol administration and an elevated serum chloramphenicol concentration point to toxicity; sepsis is supported by a positive culture or an identified infective focus.
  - Gray baby syndrome improves on stopping and clearing the drug, whereas septic shock requires source control and antimicrobials.
treatments:
- name: Drug discontinuation and supportive care
  description: >-
    Stopping chloramphenicol and supporting circulation, ventilation and
    temperature; the mainstay for gray baby syndrome and dose-dependent marrow
    suppression.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aggressive management included mechanical ventilation, inotropic support (dopamine/milrinone), norepinephrine infusion"
    explanation: Documents the intensive supportive care used for severe gray baby syndrome.
- name: Extracorporeal drug removal
  description: >-
    Continuous renal replacement therapy (the intervention used in the cited
    case), with exchange transfusion or charcoal haemoperfusion as alternatives,
    to clear massively accumulated chloramphenicol in severe toxicity. Bound to
    the renal-replacement action; NCIT exchange-transfusion (NCIT:C173284) is not
    reachable from the TreatmentTerm root (NCIT:C25218), so it is named in prose
    only.
  treatment_term:
    preferred_term: continuous renal replacement therapy
    term:
      id: NCIT:C126400
      label: Renal Replacement Therapy
  evidence:
  - reference: PMID:41602900
    reference_title: "Chloramphenicol-induced gray baby syndrome: case report and review of current literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "delayed CRRT proved pivotal in reversing toxicity in our patient"
    explanation: Reports extracorporeal removal (CRRT) reversing severe accumulation.
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hemodialysis was initiated for severe metabolic acidosis"
    explanation: A further case of extracorporeal removal (haemodialysis) for severe chloramphenicol toxicity.
- name: Vitamin B12 and B6 supplementation
  description: >-
    Large doses of vitamin B12 and B6 are given for chloramphenicol optic
    neuritis on the vitamin-deficiency hypothesis of the neurotoxicity. The
    benefit is unproven: in the cited case, hydroxocobalamin and pyridoxine
    did not recover the patient's vision. Recorded as a documented therapeutic
    approach with its outcome, not as an established treatment.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydroxocobalamin (vitamin B12)
      term:
        id: CHEBI:27786
        label: hydroxocobalamin
    - preferred_term: pyridoxine (vitamin B6)
      term:
        id: CHEBI:16709
        label: pyridoxine
  evidence:
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Treatment involves discontinuing chloramphenicol and the consideration of large doses of vitamin B12 and B6."
    explanation: States the B12/B6 approach to chloramphenicol neurotoxicity.
  - reference: PMID:23118672
    reference_title: "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "this therapy was not successful in improving his vision"
    explanation: Documents the failure of B12/B6 therapy to recover vision in the cited case.

📚

References & Deep Research

References

1

PMID:28846297

Gray Baby Syndrome (Archived).

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Chloramphenicol Toxicity · 2026-10-06T01:31:02Z · View source

De novo curation of Chloramphenicol Toxicity (MONDO:0010784). Deep research via the claude_code provider (research/Chloramphenicol_Toxicity-deep-research-claude_code.md; the run returned no PMIDs/snippets, only search-summary leads, so all evidence was fetched and quoted independently). One entry spans the three forms: dose-dependent reversible marrow suppression and gray baby syndrome are wired through the shared mitochondrial-injury mechanism (mitochondrial translation inhibition -> oxidative phosphorylation failure), while idiosyncratic aplastic anaemia is a separate arm off the exposure node (Yunis PMID:2486534 frames them as distinct). The gray-baby cardiac step and the aplastic-anaemia mechanism are marked INDIRECT_UNKNOWN_INTERMEDIATES / recorded as uncertain per the sources. Neonatal glucuronidation immaturity raises exposure; no gene is bound on that node (the chloramphenicol isoform is UGT2B7, not the drafted UGT1A1, but no primary source naming it was verified - recorded in notes). Phenotypes (all connected): ashen-gray discoloration, hypothermia, vomiting, circulatory collapse, anaemia, aplastic anaemia. Environmental (ECTO:9000360), diagnosis (serum concentration; blood-count monitoring) and a differential (other causes of aplastic anaemia) included. Evidence: Yunis review (PMID:2486534), gray baby case report/review (PMID:41602900), ocular-chloramphenicol aplastic-anaemia case-control (PMID:9723830), StatPearls gray baby chapter (PMID:28846297). No GeneReviews chapter; StatPearls chapter tagged-worthy. Validated: validate-disorders (19/19 snippets, 19 titles), validate-terms, check-entity-refs, check-causal-targets, every phenotype connected. preflight-dr not run (report had no CURIEs/PMIDs to confuse); MONDO/ECTO verified against local sqlite builds. Self red-team (pre-PR) then applied: unbound the ashen-gray phenotype from HP:0000961 Cyanosis (sources list ashen-gray and cyanosis as distinct; no HPO term for ashen-gray) and added Cyanosis as its own phenotype; swapped the blood-count-monitoring diagnosis evidence to an on-point snippet (PMID:41602900); tagged the StatPearls chapter in a top-level references block. Re-validated: 20/20 snippets, 7/7 phenotypes connected. Review round 1 (ai4c-reviewer): cited the two previously-assertion nodes (neonatal glucuronidation, oxidative phosphorylation failure) from PMID:41602900; added a Myocardial Dysfunction and Microcirculatory Failure intermediate node between OXPHOS failure and circulatory collapse (the source names the intermediates); renamed Gray Baby Circulatory Collapse -> Gray Baby Toxidrome and fanned it to the early features (fixing an inverted collapse->vomiting order), with collapse now downstream of the myocardial node; added Abdominal distension (HP:0003270) and Metabolic acidosis (HP:0001942) phenotypes; rebound Circulatory collapse to HP:0031273 Shock; bound extracorporeal removal to NCIT:C126400 Renal Replacement Therapy (reachable from C25218; exchange transfusion NCIT:C173284 is not reachable, named in prose); added a CASES_IN_LITERATURE prevalence record (19 cases, 35.3% mortality); added a peer-reviewed second evidence item to the ashen-gray phenotype and a metabolic-acidosis early-indicator diagnosis node. Kept the serum-level snippet unit-free to avoid the non-folding micro-sign (U+00B5) trap. Re-validated: 28/28 snippets, 9/9 phenotypes connected. Detail expansion (user-requested, sources PMID:42073156 and PMID:23118672, PMID:41602900 already cited): added primary peptidyl-transferase mechanism quote to the mitochondrial node; aplastic-anaemia incidence (1 in 24,000-40,000) and ~50% historical mortality; second source for the reversible dose-dependent arm; new phenotypes reticulocytopenia (HP:0001896), thrombocytopenia (HP:0001873), respiratory distress (HP:0002098), and a chronic mitochondrial neurotoxicity node -> optic neuritis (HP:0100653) + peripheral neuropathy (HP:0009830); serum threshold/target range in mg/L and monitoring cadence added to diagnosis; a neonatal sepsis/septic shock differential; haemodialysis evidence on extracorporeal removal. Re-validated: 42/42 snippets, 14/14 phenotypes connected.

Claude Code ▸

1. Disease Information

claude-haiku-4-5-20251001, claude-sonnet-5-5 10 citations 2026-10-06T01:21:19.846441

1. Disease Information

Overview. Chloramphenicol toxicity is a group of adverse drug reactions to the broad-spectrum antibiotic chloramphenicol. It has three distinct clinical forms:

Dose-dependent, reversible bone-marrow suppression. This mainly affects the erythroid lineage and can cause sideroblastic anemia.
Idiosyncratic aplastic anemia. It is rare, usually irreversible, and can occur after any route of exposure.
Gray baby syndrome. It occurs in neonates and premature infants and causes cardiovascular collapse.

Other toxicities are optic and peripheral neuropathy and hemolysis in G6PD deficiency. These are [general knowledge].

Entry-level decision. The toxicity is a pharmacologic or iatrogenic entity, and it has no heritable cause. The three forms have different mechanisms and time courses. The stub queue's entry_type decision is therefore live here: - A single DISEASE entry would need pathophysiology nodes that hold for every case. That is hard, because the forms share no mechanism. - A GROUPING of three entries, or a single entry with has_subtypes, is the more defensible option. - Record the choice in notes either way.

Synonyms (general knowledge). Chloramphenicol-induced aplastic anemia, chloramphenicol-induced bone marrow depression, gray (grey) baby syndrome, gray syndrome.

Identifiers. I did not verify any. Check MeSH, ICD-10-CM (T36.2X-, adverse effect and poisoning by chloramphenicol group), and MONDO via OAK.

Data origin. The sources are aggregate: pharmacology reviews, StatPearls, case reports and case series, and population case-control studies of aplastic anemia. They are not EHR-derived.

2. Etiology

Causal factor. Exposure to chloramphenicol is the cause. Systemic routes (IV or oral) are the classic ones. Topical and ocular exposure is a minor, contested contributor to aplastic anemia (see below).

Risk factors - Prematurity and neonatal age. - Gray baby syndrome is described in premature neonates given chloramphenicol IV or orally within two days of birth. The immature liver cannot glucuronidate the drug efficiently, and the neonatal kidney cannot excrete it and its metabolites well (PMC case report and review; StatPearls). - Another summary states that immature neonatal liver cannot synthesize and recycle UDP-glucuronyltransferase efficiently. - High dose or prolonged therapy. Marrow suppression is dose-dependent and reversible [general knowledge, consistent with the JCI-era literature below]. - Hepatic or renal impairment. These reduce clearance [general knowledge]. - Aplastic anemia. It is idiosyncratic. Genetic susceptibility has been proposed but is not established. I found no verified susceptibility locus.

Aplastic anemia risk figures (from search summaries, not verified at source) - A commonly quoted risk of fatal aplastic anemia after chloramphenicol is about 1 in 20,000 to 1 in 30,000 courses, roughly 13 times the background incidence (reported in the NTP Report on Carcinogens profile results; confirm in the document). - Case-control data are weaker than the headline figure: - One study reported an adjusted OR of 8.7 (95% CI 0.87–87.93) for exposure in the previous year. - An ocular-chloramphenicol analysis found 3 cases (2.1%) and 5 controls (0.4%) exposed, with an adjusted OR of 3.77 (95% CI 0.84–16.90). - The search summary said more than 400 cases across two large population-based studies had no chloramphenicol eye-drop use. - See the Haematologica article, PMC1873671, and PMC28472. I do not know which paper reports which number, so attribute them only after reading. - Curation note. The ocular-exposure OR confidence intervals include 1, so that data does not establish risk.

Protective factors. None established. Avoiding the drug and using alternative antibiotics in neonates is prevention, not a protective factor.

Gene–environment interactions. I found no verified data. G6PD deficiency with hemolysis is a recognized pharmacogenetic interaction [general knowledge, unverified]. It would need a source before being curated.

3. Phenotypes

Frequencies are not verified. Do not enter them without a source.

Form	Phenotype	Onset and course	HPO term (to look up)
Marrow suppression	Anemia (often with reticulocytopenia)	Dose-related, during therapy, reversible on withdrawal	Anemia; Reticulocytopenia
Marrow suppression	Sideroblastic anemia	During therapy	Sideroblastic anemia
Marrow suppression	Leukopenia, thrombocytopenia	During therapy	Leukopenia; Thrombocytopenia
Aplastic anemia	Pancytopenia, bone marrow aplasia	Idiosyncratic, can be delayed after exposure, often irreversible	Pancytopenia; Aplastic anemia
Gray baby syndrome	Abdominal distention, vomiting	Days after drug start	Abdominal distention; Vomiting
Gray baby syndrome	Hypothermia, cyanosis	Same	Hypothermia; Cyanosis
Gray baby syndrome	Cardiovascular instability, vasomotor collapse, mottled and then ashen-gray skin	Same	Hypotension or shock-type terms; Mottled skin

The gray-baby clinical picture comes from the PMC case report and StatPearls summaries.
That case report reviews 19 additional published cases. Mine it for outcomes and frequencies.
Quality-of-life data: none found.
Optic neuritis and peripheral neuropathy occur with prolonged use [general knowledge, unverified].

4. Genetic/Molecular Information

Causal genes. None. This is not a Mendelian disease.
Relevant pharmacogenes (general knowledge, needs sources):
UGT2B7 mediates chloramphenicol glucuronidation. UGT1A6 and UGT1A9 involvement is less certain.
Developmental immaturity of UGT activity is the neonatal mechanism.
Molecular target. The mitochondrial ribosome (mtDNA-encoded protein synthesis). The sources say chloramphenicol targets the 39S large subunit of the mitoribosome (T3DB summary; verify against a primary source).
Epigenetic and chromosomal data. None found.
Genetic susceptibility to aplastic anemia. Unresolved. State this as a knowledge gap, not as a gene association.

5. Environmental Information

Exposure. Systemic chloramphenicol by IV or oral route. Topical or ocular use is controversial (see Section 2).
Lifestyle factors. None.
Infectious agents. None cause the toxicity. The drug is used for severe infections such as meningitis and typhoid, where alternatives are limited [general knowledge].
ECTO term to look up. An exposure term for chloramphenicol. Run l~chloramphenicol against ECTO, and try both "anaesthetic"-style spelling variants where relevant. Re-run every search a note claims, as CLAUDE.md requires.

6. Mechanism / Pathophysiology

Causal chains

Chain A: Dose-dependent marrow suppression 1. Systemic chloramphenicol reaches hematopoietic progenitors. This is inferred from the drug's distribution [general knowledge]. 2. The drug binds the mitochondrial ribosome (39S subunit) and inhibits mitochondrial protein synthesis (T3DB summary; JCI article). 3. This depletes mtDNA-encoded respiratory-chain subunits, including cytochrome components. The JCI summary says the inhibitory effect can be explained by the drug's action on cytochrome formation by the mitochondrial protein-synthesizing system. 4. Metabolically active, rapidly dividing cells, notably the erythroid lineage, lose oxidative capacity and become cytotoxically affected. Iron utilization is impaired, which gives sideroblastic changes. The sideroblastic link is stated in the search summary as thought to be related to mitochondrial dysfunction; the detailed iron-handling steps are inferred. 5. The result is reversible erythroid-predominant marrow suppression and anemia. The reviewed source says ample evidence ties the reversible suppression to inhibition of mitochondrial protein synthesis, while the aplastic form is a separate rare complication.

Chain B: Idiosyncratic aplastic anemia (mechanism unresolved) 1. Chloramphenicol exposure occurs. 2. A susceptible host develops stem-cell injury. The mechanism is not established. Proposed routes (a toxic nitroso or nitro-reduction metabolite, or genetic susceptibility) are hypotheses, not demonstrated here. 3. Marrow aplasia and pancytopenia follow.

Do not link Chain A's mitochondrial inhibition to aplastic anemia as if causal. The sources frame them as separate complications.

Chain C: Gray baby syndrome 1. A neonate, usually premature, receives chloramphenicol. 2. Immature hepatic UDP-glucuronyltransferase activity means glucuronidation is deficient. Renal excretion is also immature (PMC). 3. Unconjugated drug accumulates to high serum concentrations. 4. Accumulated drug inhibits mitochondrial function in cardiac and other tissues. This step is the commonly proposed but not directly demonstrated link, and it needs a source before curation. 5. Cardiovascular collapse follows, with mottling, then ashen-gray skin, hypothermia, and cyanosis.

Suggested ontology terms (lookup required)

GO. Mitochondrial translation. Also consider a mitochondrial ribosome-related term for the molecular function (peptidyl transferase activity, inhibited by drug). Check the exact labels.
CL. Erythroid progenitor cell, hematopoietic stem cell, hepatocyte (glucuronidation).
CHEBI. Chloramphenicol. Look it up, and also look up chloramphenicol glucuronide if a metabolite node is wanted.
GO Cellular Component. Mitochondrion, mitochondrial large ribosomal subunit.
Modifier. Use DECREASED for mitochondrial translation (a quantitative state). Do not use LOSS_OF_FUNCTION unless you can justify it qualitatively.
Biological scale tags. MOLECULAR for ribosome inhibition, CELLULAR for erythroid suppression, ORGANISM for circulatory collapse.

Mechanism module candidates

kb/modules/ already has antimicrobial drug mechanism modules and a "treatment toxicity / side effect as mechanism" family. Run just list-modules ribosom and just list-modules mitochond and use rg -il "mitochondrial translation" kb/modules before writing new nodes.

Molecular profiling, single-cell, and screens

No data found for chloramphenicol toxicity. State "not available".

7. Anatomical Structures Affected

Primary. Bone marrow, especially the erythroid compartment. Also the circulatory system in neonates.
Secondary. Liver (site of drug metabolism). Optic nerve and peripheral nerves with chronic use [general knowledge, unverified].
Cells. Erythroid progenitors, hematopoietic stem cells, hepatocytes, cardiomyocytes (proposed).
Subcellular. Mitochondria and the mitoribosome.
Laterality. Not applicable, since the effects are systemic.
UBERON terms. Look up bone marrow, liver, and optic nerve.

8. Temporal Development

Marrow suppression. It develops during therapy, is dose-related, and is generally reversible after withdrawal.
Aplastic anemia. It can appear weeks to months after exposure, is idiosyncratic, and is often irreversible. The delay is [general knowledge]; confirm it.
Gray baby syndrome. It typically appears within the first days of therapy in neonates.
Critical period. The neonatal and premature period, when glucuronidation is immature.
Remission. Marrow suppression reverses on withdrawal. For aplastic anemia I have no verified remission data.

9. Inheritance and Population

Inheritance. None.
Incidence figures.
Aplastic anemia risk after chloramphenicol was quoted at about 1 in 20,000 to 1 in 30,000, as above.
A separate figure for background aplastic anemia incidence in Latin American countries was 1.6 per million per year, from a search summary. This is background incidence, not toxicity incidence.
If you encode Prevalence, use measure_type: UNKNOWN or a literature-based measure, not a rate you cannot quote. Gray baby syndrome today is rare, but I have no verified figure.
Demographics. Neonates and premature infants for gray baby syndrome. No verified sex ratio or geography.
Consanguinity, founder effects, anticipation, carrier frequency. Not applicable.

10. Diagnostics

All of this section is [general knowledge] unless stated. Verify with StatPearls (Gray baby syndrome and chloramphenicol chapters) and clinical guidelines.

Clinical diagnosis. Temporal association with drug exposure plus compatible findings.
Laboratory tests.
CBC with reticulocyte count. Suppression usually shows reticulocytopenia and anemia.
Marrow examination for vacuolated precursors, or aplasia in the idiosyncratic form.
Serum drug concentration monitoring. Therapeutic ranges exist, and high levels predict toxicity. Get the numbers from a guideline, not memory.
Genetic testing. Not applicable.
Differential. Neonatal sepsis and shock, other drug-induced marrow failure, and other causes of aplastic anemia.
Screening. Monitoring blood counts during therapy. Therapeutic drug monitoring in neonates.

11. Outcome/Prognosis

Marrow suppression. Reversible on drug withdrawal.
Aplastic anemia. Mortality is high. The risk is much rarer than the older literature implied, as the case-control summaries above suggest.
Gray baby syndrome. It is potentially fatal. The PMC case report with 19 reviewed cases is the best lead for mortality figures. I could not read them.
Prognostic factors. Early recognition and drug cessation, serum level, and gestational age [general knowledge].

12. Treatment

All of this is [general knowledge]. Confirm each item against a cited source before entering a treatments: block.

Stop chloramphenicol. This is the primary treatment.
Supportive care. Circulatory and respiratory support for gray baby syndrome. Transfusion for marrow suppression.
Removal of the drug. Exchange transfusion, charcoal hemoperfusion, and hemodialysis have been reported in gray baby syndrome. Check the case-report literature for the actual evidence level.
Aplastic anemia. Standard management is immunosuppressive therapy or hematopoietic stem cell transplantation. This is not specific to chloramphenicol, so reference the general aplastic anemia entry if one exists.
Experimental or trial data. None found. Run a ClinicalTrials.gov search before writing "none".
NCIT terms to look up. Supportive care, blood transfusion, hematopoietic cell transplantation, and discontinuation of therapy if NCIT has it. Apply the modality rules in CLAUDE.md. For example, NCIT:C15431 maps to CELL_THERAPY in the mechanical backfill table, and I have not checked that mapping against the ontology in this session.

13. Prevention

Primary prevention. Avoid chloramphenicol in neonates, or where alternatives exist. This is the key lesson from gray baby syndrome.
Dose control. Use serum level monitoring and dose adjustment in neonates and in hepatic or renal impairment [general knowledge].
Secondary prevention. Serial blood counts.
Public health. Regulatory restrictions and label warnings. I did not verify jurisdiction-specific policy.
Vaccines and genetic counseling. Not applicable.

14. Other Species / Natural Disease

Veterinary use and toxicity. One search result was a veterinary journal PDF (Eurasian J Vet Sci). I did not read it. It suggests animal-toxicity literature exists.
Cats. They are known for deficient glucuronidation and are sensitive to some drugs [general knowledge]. Whether chloramphenicol toxicity is documented in cats is unverified.
Food-producing animals. Chloramphenicol is banned in food animals in many jurisdictions. This is a regulatory point, not a verified toxicity statement.
NCBI Taxon, breed, and OMIA entries. None applicable (not heritable).
Zoonosis. Not applicable.

15. Model Organisms

Mitochondrial translation inhibition. The mechanism has been demonstrated in mammalian systems in the JCI-era literature (JCI). The search summary does not say which species. Read it before assigning evidence_source.
Cell models. Bone marrow cell and cell-line studies of mitochondrial protein synthesis inhibition are plausible leads. I have no verified citation.
Genetic models. None. Mouse and zebrafish models of chloramphenicol-induced marrow suppression or gray baby syndrome: not found.
Limitations. Reversible suppression is modeled by mitochondrial translation inhibition, but idiosyncratic aplastic anemia has no known model.
Databases. MGI, ZFIN and IMPC are not applicable because the cause is non-genetic.

Curation Next Steps

Resolve the MONDO ID and the lump/split decision (Section 1).
Fetch references. Run just fetch-reference on the PMC articles (PMC12833000, PMC1873671, PMC28472), the JCI article, and the Haematologica article. Get PMIDs from the fetched cache files, not from memory.
Look up every ontology term. Use OAK or the caches, in the same step as writing the CURIE. The dismech-terms skill governs this.
Assign evidence_source correctly.
Human case series: HUMAN_CLINICAL.
Mitochondrial ribosome studies in cells or isolated mitochondria: IN_VITRO.
Studies in animals: MODEL_ORGANISM.
Mark unverified links as gaps. Use KNOWLEDGE_GAP discussions for the aplastic anemia mechanism and for the cardiac step of gray baby syndrome. Do not state them as causal edges.
Add a history/ record with just new-history.

Chloramphenicol Toxicity

Ask OpenScientist

OpenScientist Report

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Environmental Factors

Diagnosis

Prevalence

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

Causal chains

Suggested ontology terms (lookup required)

Mechanism module candidates

Molecular profiling, single-cell, and screens

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Curation Next Steps

Sources